Dr. Ahn is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2520 Elisha Avenue
Zion, IL 60099Phone+1 847-748-0627
Education & Training
- University of Miami/Jackson Health SystemFellowship, Infectious Disease, 2000 - 2003
- University of Utah HealthResidency, Internal Medicine, 1997 - 2000
- University of Miami Leonard M. Miller School of MedicineClass of 1997
Certifications & Licensure
- IL State Medical License 2014 - 2026
- IA State Medical License 2020 - 2023
- FL State Medical License 2004 - 2015
- UT State Medical License 1998 - 2000
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Infectious Disease
Clinical Trials
- Trastuzumab in Treating Older Women With Early-Stage Breast Cancer Start of enrollment: 2009 Feb 05
- NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer Start of enrollment: 2016 Apr 01
- TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer Start of enrollment: 2016 Mar 14
Publications & Presentations
PubMed
- Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer WithAlterations: Results From the Targeted Agent and Profiling Utilization Registry Study.Timothy L Cannon, Michael Rothe, Pam K Mangat, Elizabeth Garrett-Mayer, Vi K Chiu
Journal of Clinical Oncology. 2024-09-20 - 1 citationsTalazoparib in Patients With Solid Tumors With/Mutation: Results From the Targeted Agent and Profiling Utilization Registry Study.Gordan Srkalovic, Michael Rothe, Pam K Mangat, Elizabeth Garrett-Mayer, Eugene R Ahn
JCO Precision Oncology. 2024-06-01 - 3 citationsSunitinib in Patients With Breast Cancer WithorAmplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study.Carmen J Calfa, Michael Rothe, Pam K Mangat, Elizabeth Garrett-Mayer, Eugene R Ahn
JCO Precision Oncology. 2024-02-01
Press Mentions
- RHSHC to Offer Oncology CareSeptember 29th, 2020
- Positive Findings from Two TAPUR™ Study Cohorts to Be Presented at 2019 ASCO® Annual MeetingMay 22nd, 2019
- 4 Doctor-Approved Strategies to Live LongerMay 29th, 2017
- Join now to see all
Professional Memberships
- Member
- NRG OncologyMember
- Society of Integrative OncologyMember
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: